When combined with another anti-cancer drug, personalised RNA vaccine led to a 44 per cent reduction in the risk of recurrence or death compared to using the drug alone, clinical trials show. PA
When combined with another anti-cancer drug, personalised RNA vaccine led to a 44 per cent reduction in the risk of recurrence or death compared to using the drug alone, clinical trials show. PA